Does lovastatin reduce the risk for the first acute major coronary event in men and women with average TC and LDL-C levels and below-average HDL-C levels?
Lovastatin reduces the risk of first acute major coronary events in patients with average LDL-C but below-average HDL-C, suggesting a need to reassess guidelines.
Lovastatin reduces the risk for the first acute major coronary event in men and women with average TC and LDL-C levels and below-average HDL-C levels. These findings support the inclusion of HDL-C in risk-factor assessment, confirm the benefit of LDL-C reduction to a target goal, and suggest the need for reassessment of the National Cholesterol Education Program guidelines regarding pharmacological intervention.
Downs et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: